Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
Sari D. Hopson, PhD, MSPH
Advertisement
Articles by Sari D. Hopson, PhD, MSPH
Advertisement
Latest Updated Articles
- COPD Exacerbation Costs in the IMPACT Study: A Within-Trial Analysis
Published: May 6th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Withdrawal of Aid Could Cause Millions of Lives Lost to HIV
2
EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy
3
Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color
4
FDA Approves Second Generic Mifepristone Pill for Abortion
5
